BioStock Investor Pitch: Prolevi Bio
Privately-owned Prolevi Bio’s goal is to improve the treatment of hypothyroidism, a common condition involving a lack of thyroid hormone. The company has developed a method that releases medicine based on the patient’s circadian rhythm. According to Prolevi Bio, this should improve the effect of the drug, something that CEO Sahil Gupta explains more about in a company presentation in BioStock’s studio.
Watch Prolevi Bio’s CEO Sahil Gupta present the company below.
